Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Angina Pectoris Drugs Global Market 2024" report has been added to ResearchAndMarkets.com's offering.
The global landscape of angina pectoris drugs is demonstrating a significant upsurge in market growth, with this in-depth analysis published to showcase the extensive developments, trends, and future projections within the industry. The comprehensive report offers a meticulous examination of the angina pectoris drugs market, bringing to light the intrinsic market forces driving the sector, which is projected to reach formidable heights in the ensuing years.
The market will grow from $11.82 billion in 2023 to $12.47 billion in 2024, at a compound annual growth rate (CAGR) of 5.5%. The market is expected to grow to $15.48 billion in 2028, at a compound annual growth rate (CAGR) of 5.6%.
Market Growth Boosted by Rising Chronic Angina Cases and Focus on Innovative Drug Solutions
In the wake of mounting incidences of chronic angina pectoris and cardiovascular diseases, the demand for effective therapeutics has sharply risen. The report unpacks the intricate factors behind this growth, ranging from demographic shifts toward aging populations and elevating instances of hypertension and diabetes to the surges in obesity rates globally. It highlights the growing emphasis on preventive cardiology and precision medicine as pivotal enablers for the expansion of the angina pectoris drugs market.
Technological Advancements and Product Innovation Spearheading Market Progress
The adoption of cutting-edge technologies and the coming of age of telemedicine are seen as key trends fostering market sustainability and growth. Remote patient monitoring systems and evidence-based studies are transforming the approach to angina pectoris drug development and application. The report explores how strategic alliances among key players in the industry, as well as regulatory breakthroughs, are smoothing the way for new product introductions and rapid market penetration.
- Escalating Prevalence of Hypertension and Diabetes Catalyzing Demand for Angina Drugs
- Telemedicine and Real-world Evidence Studies among Leading Market Trends
- Strategic Alliances and Regulatory Advancements Influencing Market Dynamics
The thorough market investigation presents granular insights into the competitive landscape of the angina pectoris drugs market. It emphasizes recent developments like novel FDA-approved therapeutics and strategic acquisitions, which are poised to restructure market contours and fortify the product portfolios of industry forerunners.
Regional Insights and Market Delineation
This report elucidates North America holding the reins as the largest region in the angina pectoris drugs market sphere in 2023. However, Asia-Pacific is forecasted to emerge as the fastest-growing region, thanks to burgeoning disease prevalence and healthcare advancements. To offer a bird's-eye view of the market landscape, the report segues into a detailed segmentation based on drug classes including nitrates, antiplatelet agents, beta-blockers, and others. The analysis accentuates the importance of such distinctions, elucidating the specific application of these drug classes across various healthcare settings.
The research document offers a comprehensive evaluation of market size, shares, and the anticipated trajectory, thereby serving as an invaluable tool for stakeholders to gauge the potential and respond to the market stimuli effectively. It synthesizes a wealth of data into an actionable blueprint for navigating the complex environment of angina pectoris drugs.
In the realm of the angina pectoris drugs market, the cascading effects of several drivers, from clinical to corporate, are thoroughly explicated, offering stakeholders rich, data-backed intelligence to tactically steer their operations. The report stands as a testament to the dynamic market forces at play and the unwavering commitment of industry players to address the mounting healthcare challenges associated with angina pectoris.
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- Bayer AG
- Novartis AG
- AstraZeneca PLC
- Amgen Inc.
- Gilead Sciences Inc.
- Bausch Health Companies Inc.
- Merck & Co Inc.
- Eli Lilly and Company
- Otsuka Pharmaceutical Co Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Abbott Laboratories
- AbbVie Inc.
- Sun Pharmaceutical Industries Limited
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Sanofi SA
- Sun BioPharma Inc.
- Atox Bio Inc.
- CalciMedica Inc.
- D-Pharm Ltd.
- Dynavax Technologies Corporation
- Fresenius SE & Co KGaA
- Olympus Corporation
- SCM Lifescience Co. Ltd.
- Allergan plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Vertex Pharmaceuticals Incorporated
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/r/fyns9n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
